Type of Study:

Interventional

Study Design:

Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

pharmacokinetic data

Principal Investigator

James Russell, FRCp

Investigator Role:

Principal Investigator

Investigator Affiliation:

Alberta Cancerboard

Authority:

Canada: Health Canada

Study ID:

10156

NCT ID:

NCT00156858

Start Date:

January 1998

Completion Date:

December 2010

Related Keywords:

• Hematologic Malignancy
• pharmacokinetics
• transplantation
• busulfan
• Neoplasms
• Hematologic Neoplasms

Name	Location